Dichloroacetate (DCA) and Lung Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Dichloroacetate (DCA) and Lung Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Dichloroacetate (DCA) in the context of Lung Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your oncologist for personalized guidance.

Compound Overview

Dichloroacetate (DCA) (Metabolic / Pyruvate Dehydrogenase Kinase Inhibitor) — Not FDA-approved; investigational for cancer and metabolic disorders

Mechanism of action: Inhibits PDK; shifts glucose metabolism from glycolysis to OXPHOS; reactivates mitochondria in cancer cells; pro-apoptotic

Current evidence level: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity

2026 Research Landscape

Research has directly examined Dichloroacetate (DCA) in Lung Cancer, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Dichloroacetate (DCA) affects the biological pathways involved in Lung Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Dichloroacetate (DCA) in Lung Cancer patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Dichloroacetate (DCA)[tiab]) AND (Lung Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Dichloroacetate (DCA) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Dichloroacetate (DCA) + Lung Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Lung Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Dichloroacetate (DCA) for Lung Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Dichloroacetate (DCA) Lung Cancer' filtered to the last 2 years. The current evidence level is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity.

Are there any 2025-2026 clinical trials for Dichloroacetate (DCA) in Lung Cancer?

Check ClinicalTrials.gov with 'Dichloroacetate (DCA)' as intervention and 'Lung Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Dichloroacetate (DCA) in Lung Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Phase I/II trials in glioblastoma and other cancers; peripheral neuropathy dose-limiting toxicity. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.